Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APPOINT 2.0
NCT06488781Phase 2Recruiting
- Sponsor
- University of Oklahoma
- Start
- Apr 2025
- Primary completion
- Dec 2028
- Modality
- Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of azithromycin and cefazolin in puerperal infection (2 arms), sponsored by University of Oklahoma. Primary endpoint: Rate of cesarean delivery. Started Apr 2025; status: recruiting.
02
Drugs
azithromycincefazolin
03
Conditions
puerperal infection
Beyond the preview
Go deeper on NCT06488781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06488781.